Atul Pande is a drug and device development expert with 25 years of industry experience.
He currently serves as Chief Medical Officer of Boston-based PureTech Health. He is the former Senior Vice President, Head of Neuroscience, and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline.
Dr. Pande has been active in the development of multiple investigational and now marketed drugs while holding various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert, and Lilly Research Laboratories.
His experience includes drug development, registration, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, traumatic brain injury, and Alzheimer’s and Parkinson’s diseases.
Dr. Pande is a psychiatrist and fellow of several scientific societies, including the American Psychiatric Association. He currently serves; on the Board of Directors of PureTech Health’s Karuna Pharmaceuticals. He also sits on the Board of Axovant Sciences (NASDAQ:AXON) and on the Scientific Advisory Boards of Datavant, Centrexion Corporation and Cennerv Pharma.
Dr. Pande began his career as a professor at the University of Michigan Medical School where his research focused on mood disorders. He has published over 50 peer-reviewed scientific papers and over 100 abstracts, book chapters, and book reviews.